The most compelling healthtech founders often start with a personal story, not a business plan. For Jean-Jacques "JJ" Schoch, a thirty-year veteran of consumer software architecture, that story is Long COVID. His recovery, he says, became the blueprint for a new kind of digital health company [LinkedIn, September 2026]. Luminara Biosciences, the Los Angeles-based startup he co-founded in 2024, is now raising $1.5 million at a $5 million pre-money valuation to turn that personal protocol into a commercial wellness intelligence platform [LinkedIn, September 2026]. It is a bet that the chronic illness and post-viral recovery market, still underserved by traditional medicine, is ready for a structured, AI-guided approach built by patients.
A protocol, not just an app
Luminara's initial wedge is a patented protocol called Risiliora™, which Schoch developed to address two specific Long COVID patterns his research identified: viral persistence and autonomic dysfunction [luminarabiosciences.com]. This is not a passive symptom tracker. The company frames it as an active, personalized recovery program, a distinction that moves it from the crowded wellness app category toward something resembling a digital therapeutic. The platform's second core program, Amara™, is a 20-session nervous system regulation curriculum created by co-founder Dolly Mirella Ramirez, a certified somatic practitioner [luminarabiosciences.com]. Together, they aim to form a closed-loop system where physiological data and user-reported outcomes inform a continuously adapting care plan.
The team behind the bet
The founding team reflects the product's dual nature: part clinical protocol, part empathetic support. Schoch's background is in building resilient, user-facing software systems at Norton and iolo, experience he applies to platform architecture and AI-system design [jjschoch.com, 2026]. Ramirez brings a practitioner's lens, with certifications across six nervous-system regulation disciplines [LinkedIn, 2026]. An adviser, Alexandra Schoch, contributes cognitive science research from Columbia University to shape the platform's "recognition-first" intake process, which is designed to start with a person's identity and health patterns rather than a blunt diagnosis [luminarabiosciences.com]. This blend of software rigor and somatic practice is the team's core hypothesis.
| Role | Name | Key Background |
|---|---|---|
| Founder, Chairman, Chief Scientist | Jean-Jacques "JJ" Schoch | 30+ years consumer software (Norton Antivirus, System Mechanic); developed Risiliora™ post-Long COVID [jjschoch.com, 2026]. |
| Co-founder | Dolly Mirella Ramirez | Certified somatic practitioner; creator of the Amara™ nervous-system program [LinkedIn, 2026]. |
| Adviser | Alexandra Schoch | Cognitive Science student at Columbia University; advises on intake architecture [LinkedIn, 2026]. |
The regulatory and evidence gap
For all its personal genesis, Luminara operates in a space where regulatory context and peer-reviewed evidence are the ultimate currencies. The company's public claims of a U.S. patent for Risiliora™ are a start, but patents protect intellectual property, not prove clinical efficacy [luminarabiosciences.com]. The platform appears oriented toward direct-to-consumer sales, which allows for faster iteration but also places it outside the rigorous validation pathways of FDA-cleared software as a medical device. The risks here are clear and significant.
- Proof of efficacy. All product claims are currently company-provided. Without published clinical data or third-party validation, it is impossible to assess the protocol's impact compared to standard supportive care or other digital interventions.
- Market navigation. The chronic illness and Long COVID support landscape is fragmented, ranging from clinical research programs to informal patient communities. Demonstrating superior outcomes,and convincing users to pay for them,remains an unproven commercial motion.
- Team translation. While the founders' backgrounds are relevant, the leap from consumer software and somatic practice to scaling a clinical-grade digital health intervention requires additional expertise in clinical research, medical affairs, and possibly regulatory strategy. The company's participation in a Founder Institute cohort suggests an awareness of the need for structured mentorship, particularly around go-to-market and evidence generation [LinkedIn, September 2026]. The next twelve months will be about converting that mentorship into tangible traction: securing the pre-seed round, initiating a pilot study with measurable endpoints, and perhaps partnering with a research institution to add credibility.
For patients with post-acute infection syndromes like Long COVID, the standard of care today is often a frustrating patchwork. It typically involves managing a constellation of symptoms,fatigue, brain fog, autonomic dysfunction,across multiple specialists, with few targeted therapies available. Care is supportive, not curative, and the burden of coordinating it falls heavily on the individual. Luminara Biosciences is betting that a unified, protocol-driven platform can bring order to this chaos. Its success hinges not on the elegance of its AI, but on whether it can deliver a better quality of life for the people it aims to serve.
Sources
- [LinkedIn, September 2026] Jean-Jacques Schoch's LinkedIn Profile | https://www.linkedin.com/in/jjschoch
- [luminarabiosciences.com] Luminara Biosciences - About Us | https://luminarabiosciences.com/about.html
- [jjschoch.com, 2026] Jean-Jacques (J.J.) Schoch | https://jjschoch.com
- [LinkedIn, 2026] Dolly Mirella Ramirez's LinkedIn Profile | https://www.linkedin.com/in/dolly-mirella-ramirez
- [LinkedIn, 2026] Alexandra Schoch's LinkedIn Profile | https://www.linkedin.com/in/alexandra-schoch